1. Home
  2. EYEN vs JAGX Comparison

EYEN vs JAGX Comparison

Compare EYEN & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EYEN
  • JAGX
  • Stock Information
  • Founded
  • EYEN 2014
  • JAGX 2013
  • Country
  • EYEN United States
  • JAGX United States
  • Employees
  • EYEN N/A
  • JAGX N/A
  • Industry
  • EYEN Biotechnology: Pharmaceutical Preparations
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • EYEN Health Care
  • JAGX Health Care
  • Exchange
  • EYEN Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • EYEN 3.7M
  • JAGX 3.1M
  • IPO Year
  • EYEN 2018
  • JAGX N/A
  • Fundamental
  • Price
  • EYEN $1.12
  • JAGX $4.59
  • Analyst Decision
  • EYEN Hold
  • JAGX
  • Analyst Count
  • EYEN 4
  • JAGX 0
  • Target Price
  • EYEN $2.00
  • JAGX N/A
  • AVG Volume (30 Days)
  • EYEN 495.7K
  • JAGX 39.3K
  • Earning Date
  • EYEN 05-14-2025
  • JAGX 03-31-2025
  • Dividend Yield
  • EYEN N/A
  • JAGX N/A
  • EPS Growth
  • EYEN N/A
  • JAGX N/A
  • EPS
  • EYEN N/A
  • JAGX N/A
  • Revenue
  • EYEN $31,832.00
  • JAGX $11,689,000.00
  • Revenue This Year
  • EYEN $23,413.60
  • JAGX $18.18
  • Revenue Next Year
  • EYEN $400.98
  • JAGX $40.06
  • P/E Ratio
  • EYEN N/A
  • JAGX N/A
  • Revenue Growth
  • EYEN 2557.09
  • JAGX 19.75
  • 52 Week Low
  • EYEN $1.06
  • JAGX $4.40
  • 52 Week High
  • EYEN $124.80
  • JAGX $540.00
  • Technical
  • Relative Strength Index (RSI)
  • EYEN 27.91
  • JAGX 19.96
  • Support Level
  • EYEN $1.06
  • JAGX $4.40
  • Resistance Level
  • EYEN $1.19
  • JAGX $4.97
  • Average True Range (ATR)
  • EYEN 0.10
  • JAGX 0.83
  • MACD
  • EYEN 0.05
  • JAGX 0.15
  • Stochastic Oscillator
  • EYEN 9.05
  • JAGX 0.87

About EYEN Eyenovia Inc.

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: